Federal Government
Therapeutic Goods Administration

FEDERAL GOVERNMENT

1. Authorised Prescriber – authorisation of doctor for a cohort of patients

2. Special Access Scheme (SAS) – authorisation for an individual patient

  • Guidance for health practitioners and sponsors
  • Special Access Scheme forms
  • Contact for enquiries and submission of applications
    • Category A is a notification pathway for terminally ill patients and may only be used for imported products;
    • Category B is an application pathway where the patients do not fit Category A and the product does not have an established history of use under Category C. This is likely the most applicable SAS Category for medicinal cannabis
    • Category C is a notification pathway where products have an established history of use and are listed together with their indications

ADDITIONAL RESOURCES

Please contact AusCann via medicalenquiries@auscann.com.au for further information, education or support.

DISCLAIMER

The information on this website is provided for the purpose of disseminating information pertaining to cannabinoid medicines and is targeted to health professionals, not the general public. Nothing on this website is intended to be used as medical advice and it is not intended to be used to prevent, diagnose, treat or cure any disease or condition. The information on this website has been compiled from a variety of sources and should not be considered complete. It is provided on an ‘as is’ basis, without any warranties, either express or implied.
The website contains links to external sites. AusCann takes reasonable care in selecting linking websites but accepts no responsibility for material contained on an external site. It is the responsibility of the user to ensure make their own decisions regarding accuracy, currency, reliability and correctness of information on the external sites. The links are provided for convenience and do not constitute an endorsement of any third party products or services. Views put forward on third party websites do not necessarily match the views of the Company.